Brain+: Have Laid the Groundwork for Future Commercial Success - Analyst Group

In 2022, Brain+ had a successful commercial introduction of its CST-Therapist Companion dementia product in Denmark and secured the first sales contract. Further, Brain+ attracted new talents within DTx and Alzheimer’s, made important advance-ments in R&D pipeline, received positive feedback on core technologies, and secured additional funding. With yet another contract secured in Q2-23, ongoing dialogues with other Danish municipalities and the upcoming market introduction in Germany, Brain+ is now on the path to becoming a commercial business. Analyst Group estimates net sales of EUR 3.0m by 2025, and with an applied EV/S multiple, a potential present value per share of DKK 1.12 is derived in a Base scenario.

Länk till analysen i sin helhet: https://analystgroup.se/analyser/brain-q1-23/